... deferiprone (DFP) combined with 40 mg/kg/dose s.c. desferrioxamine (DFO) twice weekly were given to transfusion-dependent β-thalassemia children. Results: Enrolled patients (9 with β-thalassemia major and 33 with β-thalassemia hemoglobin E), ranging from 3 to 18 years in age, were divided into 3 groups; group...

... in overloaded rats in comparison with normal rats. The iron decrease in liver, spleen, brain, kidney, and muscle in highly anaemic rats was significant, while the iron increase in liver, heart, and muscle in iron-overloaded rats was evident in comparison with normal rats. After treatment with desferrioxamine...

...F. Schettini; A. Mautone; L. Cavallo; M. Altomare; O. Montagna; L. Dell’Edera A longitudinal study has been conducted on serum ferritin concentrations in children with thalassemia major treated with desferrioxamine (DFO), both intramuscularly and by continuous subcutaneous infusion, in order...

...I. Bianco; B. Graziani; M. Lerone; P. Congedo; G.F. Clemente; G. Ingrao; F. Ciccone; G.D. di Nucci; F. Mandelli; G. Isacchi The effects of slow subcutaneous (s.c.) infusions of desferrioxamine (Des-feral: DF) on iron metabolism and excretion were studied in 6 thalassaemia major patients...

...Dario Conte; Lucia Brunelli; Luciana Ferrario; Clara Mandelli; Maurizio Quatrini; Pietro Velio; Paolo A. Bianchi The effect on urinary iron excretion (UIE) of vitamin C administered orally 2 h after the start of an 8-hour desferrioxamine (DF) i.v. infusion was studied in 12 patients with untreated...

.... Desferrioxamine Iron Lipid peroxidation Oxygen radicals Sickle cell anaemia Haemoglobin. Proc. Int. Meeting, London 1986 Acta haemat. 78: 105-108(1987) © 1987 S. K arger AG, Basel 0001-579 2 /8 7 /0 7 8 3 -0 105 S 2.75/0 Role of Membrane-Bound Haemoglobin Products in Oxidative Damage in Sickle Cell...

...Martin J. Pippard This paper reviews the factors governing the rate of iron loading and iron toxicity in the thalassaemia syndromes and sickle cell disease. It outlines the main determinants of iron mobilization by the iron-chelating drug, desferrioxamine, together with the effects of this drug...

... that caused by an equivalent dose of desferrioxamine. These compounds (CP20 through CP24) also caused significant excretion of 59 Fe when administered orally. Compounds CP21, CP22 and CP24 were significantly more active than compounds CP20 and CP23. It is concluded that the N-ethyl or N-propyl 3-hydroxy-pyrid...

...M.A. Aldouri; B. Wonke; A.V. Hoffbrand; D.M. Flynn; S.E. Ward; J.E. Agnew; A.J.W. Hilson Cardiac scintigraphy has been performed in 60 β-thalassaemia major patients aged 8-35 years who received regular blood transfusions and subcutaneous desferrioxamine (DFX) chelation. Fifty-seven showed...

...Alain Bel; Emmanuel Martinod; Philippe Menasché Cardiopulmonary bypass and the superimposed period of ischemia-reperfusion are situations in cardiac surgery that promote free radical generation. In these conditions, most animal and clinical studies have demonstrated the role of desferrioxamine...

... those receiving desferrioxamine therapy. Various autoantibodies such as antihistone antibodies and its subfractions H1, H2A-H4B, H2B, H3, ANF, anti-dsDNA, anti-nRNP, anti-Sm, ANCA and rheumatoid factor were tested. Out of 180 patients 50 patients (27.8%) were on desferrioxamine therapy, and 60 patients...

... to desferrioxamine (DFO), 128 patients receiving subcutaneous DFO in doses from 21 to 39 mg/kg/day were studied. These patients had received their total weekly dose of DFO according to two different methods. The first group (QOD group of 52%) had received it on an every other day basis. The second group (QD group...

.... The responses suggest that nowadays patients begin blood transfusions, and most use desferrioxamine (84.8%), but iron-related complications, including life-threatening ones such as heart disease, are still common. Conclusions: There remains a need to improve the management of thalassemia, as many patients...

...Y. Aydinok; G. Nisli; K. Kavakli; C. Coker; M. Kantar; N. Çetingül The effectiveness of the sequential use of deferiprone and desferrioxamine (DFO) in children with thalassaemia major was examined. Seven thalassaemic children in whom urinary iron induced by deferiprone was sufficient to maintain...

...H.S. Al-Rimawi; M. Al-Sheyyab; A. Batieha; H. El-Shanti; F. Abuekteish The effectiveness of desferrioxamine (DFO) in ameliorating the severity of the acute haemolysis of glucose-6-phosphate dehydrogenase (G6PD) deficiency was studied in 167 children with G6PD deficiency during an acute haemolytic...